In brief
McKinsey’s Johannesburg operations faced allegations of bribing officials related to contracts with state-owned enterprises, culminating in the firm’s significant legal penalties amidst ongoing scrutiny of its practices.
McKinsey & Company has consented to pay over $122 million in a settlement to address a felony bribery investigation linked to its operations in South Africa, according to a recently unsealed court filing by federal prosecutors in New York. This settlement represents another chapter in the firm's growing list of legal troubles, having previously paid around $1 billion for settlements related to its involvement with opioid manufacturers.The financial penalty, outlined in a deferred prosecution agreement (DPA), stipulates that the bribery charge against McKinsey will be dismissed after three years if the firm complies with the outlined conditions. In conjunction with this settlement, Vikas Sagar, a former senior partner and leader in McKinsey's Johannesburg office, has pleaded guilty to conspiracy to violate anti-corruption laws, as per prosecutors’ statements.The bribery allegations date back over a decade, originating from McKinsey's work with two South African state-owned companies: one responsible for the country's ailing electricity supply and the other managing its freight rail and port systems. Sagar reportedly used confidential information about those companies to secure lucrative consulting contracts, with portions of the payments allegedly funneled as bribes to government officials, netting McKinsey profits of approximately $85 million.Damian Williams, the U.S. Attorney for the Southern District of New York, emphasized McKinsey's involvement in a prolonged bribery scheme that secured an array of profitable consulting engagements. A 2018 New York Times investigation had already cast a shadow over McKinsey’s dealings in South Africa, labeling it as perhaps the firm’s most significant misstep in its nearly century-long history. Shortly after, revelations of McKinsey's extensive role in facilitating Purdue Pharma's sales efforts during the opioid crisis drew further scrutiny, with a federal criminal investigation linked to those actions ongoing.
